Secondary leukaemia after cure for locally advanced NSCLC: Alkylating type secondary leukaemia after induction therapy with docetaxel and carboplatin for NSCLC IIIB

Lung Cancer

Volumn 44, Issue 2, 2004, Pages 261-265

  Griesinger, Frank ^a   Metz, Michael ^a   Trümper, Lorenz ^a   Schulz, Thomas ^a   Haase, Detlef ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Carboplatin; Docetaxel; Induction chemotherapy; NSCLC; Radiotherapy; Therapy related AML; Therapy related MDS

Indexed keywords

AZATHIOPRINE; CARBOPLATIN; DOCETAXEL; PYRIDOSTIGMINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADJUVANT CHEMOTHERAPY; AGED; ALKYLATION; ANEMIA; CANCER REGRESSION; CANCER STAGING; CASE REPORT; CHROMOSOME 5; CHROMOSOME 7; CLINICAL FEATURE; DATA ANALYSIS; DISEASE SEVERITY; DOSE RESPONSE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; KARYOTYPE; LABORATORY TEST; LEUKEMIA; LUNG NON SMALL CELL CANCER; MALE; METASTASIS; MONOSOMY; MYASTHENIA GRAVIS; MYELODYSPLASTIC SYNDROME; PANCYTOPENIA; PRIORITY JOURNAL; REVIEW;

EID: 1842685100     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2003.11.015     Document Type: Article

References (22)

1. Smith S.M., Le Beau M.M., Huo D., Karrison T., Sobecks R.M., Anastasi J.et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 102:2003;43-52.
2. Levine E., Bloomfield C. Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Sem. Oncol. 19:1992;47-84.
3. Rowley J., Golomb H., Vardiman J. Nonrandom chromosome abnormalities in acute leukemia and dysmyelopoetic syndromes in patients with previously treated malignant disease. Blood. 58:1981;759-767.
4. Pedersen-Bjergaard J. Radiotherapy- and chemotherapy-induced myelodysplasia and acute myeloid leukemia. Rev. Leuk. Res. 16:1992;61-65.
5. Pedersen-Bjergaard J., Philip P., Larsen S., Andersson M., Daufaard E., Ersboll J.et al. Therapy-related myelodysplasia and acute myeloid leukemia cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the copenhagen series. Leukemia. 7:1993;1975-1986.
6. Pedersen-Bjergaard J., Rowley J. The balanced and unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood. 83:1994;2780-2786.
7. Bloomfield C., Archer K., Lillingto D., Kaneko Y., Head D., Dal Cin P. 11q23 Balanced translocations (BT) in therapy-associated acute leukemia or myelodysplastic syndrome (t-AL/MDS) are associated with distinctive prior therapeutic exposures and clinical features including adverse outcome: report from an International Workshop (IW). Blood. 98(Suppl I):2001;458a.
8. Pedersen-Bjergaard J., Osterlind K.M.H., Philip P., Pedersen A., Hansen H. Acute nonlymphocytic leukemia, preleukemia and solid tumors following intensive chemotherapy of small cell carcinoma of the lung. Blood. 66:1985;1393-1397.
9. Chak L., Sikic B., Tucker M., Horns R., Cox R. Increased incidence of acute nonlymphocytic leukemia following therapy in patients with small cell carcinoma of the lung. J. Clin. Oncol. 2:1984;385-390.
10. Herse B., Dalichau H., Wörmann B., Hemmerlein B., Schmidberger H., Hess C.et al. Outpatient induction chemotherapy with docetaxel/carboplatin in advanced non-small-cell lung cancer (NSCLC). Thorac. Cardiovasc. Surg. 46:1998;298-302.
11. Travis L.B., Holowaty E.J., Bergfeldt K., Lynch C.F., Kohler B.A., Wiklund T.et al. Risk of leukaemia after platinum-based chemotherapy for ovarian cancer. N. Engl. J. Med. 340:1999;351-357.
12. Kwong Y., Au W., Liang R. Acute myeloid leukemia after azathioprine treatment for autoimmune diseases: association with -7/7q. Cancer Genet Cytogenet. 104:1998;94-97.
13. Dombret H., Marolleau J. De novo acute myeloid leukemia in patients with Crohn's disease. Nouv. Rev. Fr. Hematol. 37:1995;193-196.
14. Philpott N., Elebute M., Powles R., Treleaven J.G., Gore M., Dainton M.et al. Platinum agents and secondary myeloid leukaemia: two cases treated only with platinum-based drugs. Br. J. Haematol. 93:1996;884-887.
15. Colon-Otero G., Malkasian G., Edmonson J. Secondary myelodysplasia and acute leukemia following carboplatin-containing combination chemotherapy for ovarian cancer. J. Natl. Cancer Inst. 58:1993;1858-1860.
16. Dissing M., LeBeau M., Pedersen-Bjergaard J. Inversion of chromosome 16 and uncommon rearrangements of the CBFB and MYH11 genes in therapy-related acute myeloid leukemia: rare events related to DNA-topoisomerase II inhibitors? J. Clin. Oncol. 16:1998;1890-1896.
17. Seymour J., Juneja S., Campbell L., Ellims P., Estey E. Prince H: secondary acute myeoloid leukemia with inv(16): report of two cases following paclitaxel-containing chemotherapy and review of the role of intensified ara-C therapy. Leukemia. 13:1999;1735-1740.
18. Haase D., Binder C., Bunger J., Fonatsch C., Streubel B., Schnittger S.et al. Increased risk for therapy-associated hematologic malignancies in patients with carcinoma of the breast and combined homozygous gene deletions of glutathione transferases M1 and T1. Leuk. Res. 26:2002;249-254.
19. Perentesis J.P. Genetic predisposition and treatment-related leukemia. Med. Pediatr. Oncol. 36:2001;541-548.
20. Arai Y., Hirose N., Yamamura K., Nagai M., Jang H., Hattori Y.et al. A patient with genetic deletions of glutathione-S-transferase T1 and M1 who developed non-small-cell lung cancer and myelodysplastic syndromes. Am. J. Med. Sci. 18:1999;424-427.
21. Garte S., Gaspari L., Alexandrie A.K., Ambrosone C., Autrup H., Autrup J.L.et al. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol. Biomarkers Prev. 10:2001;1239-1248.
22. Haase D., Feuring-Buske M., Könemann S., Troff C., Verbeek W., Hiddemann W.et al. Evidence for malignant transformation in acute myeloid leukemia at the level of early hematopoietic stem cells by cytogenetic analysis of CD34+ subpopulations. Blood. 86:1995;2906-2912.